“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?

Схожі ресурси

• P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
  за авторством: Sandra Huber, та інші
  Опубліковано: (2023-08-01)
• Two ways to complex karyotype in MDS—the role of del(5q) and TP53
  за авторством: Sandra Huber, та інші
  Опубліковано: (2025-05-01)
• P411: SF3B1 MUTATIONS IN AML ARE STRONGLY ASSOCIATED WITH MECOM REARRANGEMENTS AND MAY BE INDICATIVE OF AN MDS PRE-PHASE
  за авторством: S. Huber, та інші
  Опубліковано: (2022-06-01)
• “Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?
  за авторством: Constance Baer, та інші
  Опубліковано: (2019-08-01)
• Detection of <I>ABL1</I> kinase domain mutations in therapy-naïve <I>BCR-ABL1</I>-positive acute lymphoblastic leukemia
  за авторством: Constance Baer, та інші
  Опубліковано: (2021-11-01)